Loading company…
Haifa-based medical technology company whose ArtiFascia dural repair implant has 510k clearance for the U.S. market.
Nurami Medical develops the ArtiFascia dural repair implant, which completed an 85-patient clinical study and has 510k clearance for the U.S. market. Sales are made directly to hospitals and surgical centers. Founded in 2014 in Haifa, Israel, the company raised USD 30 mn in a Series B round on February 13, 2025, led by Almeda Ventures, with participation from GlenRock Israel. Hannoch Marksheid is CEO.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in